PHVS (Pharvaris NV) EBITDA per Share: $-3.23 (TTM As of Mar. 2026)


PHVS Pharvaris NV PHVS
22 GF Score
Price $35.02
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV EBITDA per Share?

Pharvaris NV PHVS -2.39% 22 EBITDA per Share is $-3.23 as of Mar. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,136 Biotechnology companies, Pharvaris NV ranks worse than 76.94% on this metric.

Pharvaris NV's EBITDA per Share for the three months ended in Mar. 2026 was $-0.78. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.23.

During the past 3 years, the average EBITDA per Share Growth Rate was -7.10% per year. During the past 5 years, the average EBITDA per Share Growth Rate was -21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Pharvaris NV's EBITDA per Share or its related term are showing as below:

PHVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -135.4   Med: -38.4   Max: -7.1
Current: -7.1

During the past 9 years, the highest 3-Year average EBITDA per Share Growth Rate of Pharvaris NV was -7.10% per year. The lowest was -135.40% per year. And the median was -38.40% per year.

PHVS's 3-Year EBITDA Growth Rate is ranked worse than
76.94% of 1136 companies
in the Biotechnology industry
Industry Median: 14.85 vs PHVS: -7.10

Pharvaris NV's EBITDA for the three months ended in Mar. 2026 was $-51.06 Mil.

During the past 3 years, the average EBITDA Growth Rate was -29.30% per year. During the past 5 years, the average EBITDA Growth Rate was -41.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 9 years, the highest 3-Year average EBITDA Growth Rate of Pharvaris NV was -29.30% per year. The lowest was -131.70% per year. And the median was -49.40% per year.


Pharvaris NV  (NAS:PHVS) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Pharvaris NV EBITDA per Share Related Terms


Pharvaris NV EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV EBITDA per Share Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only -2.01 -2.73 -2.75 -2.82 -3.35

Pharvaris NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -0.85 -0.75 -0.85 -0.78
PHVS
22GF Score
Pharvaris NV PHVS
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Pharvaris NV's EBITDA per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA per Share(A: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-198.367/59.159
=-3.35

Pharvaris NV's EBITDA per Share for the quarter that ended in Mar. 2026 is calculated as

EBITDA per Share(Q: Mar. 2026 )
=EBITDA/Shares Outstanding (Diluted Average)
=-51.06/65.424
=-0.78

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $-3.23 mean?
Pharvaris NV (PHVS) has a EBITDA per Share of $-3.23 as of Mar. 2026. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #874 out of 1136 companies in the Biotechnology industry, placing it in the top 76.9%.
Is Pharvaris NV's EBITDA per Share too high?
Pharvaris NV's current EBITDA per Share is $-3.23. Based on the distribution chart, Pharvaris NV ranks #874 out of 1136 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's EBITDA per Share compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #874 out of 1136 companies for EBITDA per Share. This places Pharvaris NV in the lower half of its industry. The industry median EBITDA per Share is 14.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Pharvaris NV and its competitors. For the Biotechnology industry, the median EBITDA per Share is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharvaris NV's current EBITDA per Share is $-3.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current EBITDA per Share of $-3.23. The current EBITDA per Share is $-3.23. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current EBITDA per Share is $-3.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.02
Price